Market Overview

Cydan Awards Four Scholarships to Support Innovations Impacting Individuals with Rare Conditions

  • Partners with 2018 MassChallenge to Recognize and Support Life
    Science Pioneers

Cydan II Inc., an orphan drug accelerator dedicated to creating
therapies that impact the lives of people living with rare genetic
diseases, today announced it has selected four start-up organizations
and companies to receive $5,000 scholarships to support innovations that
impact the lives of people with rare conditions. These teams will
receive the 2018 Cydan Scholarships in partnership with MassChallenge

"These innovators of technology and science have committed to developing
products, devices and services targeting rare diseases to improve the
lives of patients," said Chris Adams, Ph.D., Co-Founder and Chief
Executive Officer at Cydan. "We share a kindred spirit with these
organization as we work creatively to accelerate meaningful new
treatments for patients with rare diseases. We are excited to support
these promising start-ups and follow their progress during the 2018
MassChallenge and beyond."

In addition to the financial commitment, Cydan, as a MassChallenge
sponsor, will provide hands-on mentorship and support to the companies.

The 2018 Scholarship winners are:

  • Meter Therapeutics is researching one of life's greatest
    mysteries —intractable hiccups! While many think of the hiccups as a
    cute annoyance, chronic hiccups are a rare and debilitating condition
    affecting patients already struggling with cancer, heart disease,
    dialysis, and surgery. To date, clinicians and patients have had few
    treatment options and little data to support their use. Meter is
    working to replace a 1950's-era antipsychotic drug with a new standard
    of care for chronic hiccups.
  • Remora Therapeutics is a preclinical-stage biotechnology company
    focused on developing novel platelet-based cell therapies. The
    technology is designed to engineer platelets to fight disease and
    improve the quality of life for patients living with debilitating
  • Oxalo
    is developing a novel drug therapy to treat and
    prevent recurrent kidney stones, as well as other renal diseases
    caused by high levels of oxalate in the body.
    is an invitation-only network of consented
    patients and caregivers living with rare disease who are engaged in
    community-powered science. Caregivers and medical professionals can
    track and share real-time health information in order to collectively
    evaluate the effectiveness of therapies, diet and other interventions.

MassChallenge Boston sponsors, such as Cydan, awarded scholarships to
eligible companies participating in the 2018 Accelerator Program. Other
scholarship sponsors include BNY Mellon, Microsoft and MassCEC.

About Cydan

Cydan is an orphan drug accelerator dedicated to delivering therapies
that will significantly improve the lives of people living with rare
genetic diseases. The company evaluates experimental new therapies and
advances those with the highest potential to be disease modifying
treatments. Cydan's goal is to launch new companies focused on
developing promising therapies for rare genetic diseases with high unmet
medical need. Cydan was founded in 2013 by a management team with
extensive drug discovery, clinical development and business development
experience and is financed by leading life sciences investors including
New Enterprise Associates (NEA), Pfizer Venture Investments,
Lundbeckfonden Ventures, Longitude Capital, and Alexandria Venture
Investments. Cydan is based in Tech Square in Cambridge, Mass. For more
information, visit or
contact the company at

View Comments and Join the Discussion!